Cubist Systematic Strategies, LLC Kinnate Biopharma Inc. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$2.24 - $2.66 $18,872 - $22,410	-8,425 Reduced 67.25%	4,102 $10,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $2.5 $33,372 - $77,972	-31,189 Reduced 71.34%	12,527 $29,000
Q3 2023 Nov 14, 2023	SELL	$1.38 - $3.31 $92,730 - $222,418	-67,196 Reduced 60.58%	43,716 $61,000
Q2 2023 Aug 14, 2023	BUY	$2.33 - $6.84 $258,424 - $758,638	110,912 New	110,912 $336,000
Q4 2022 Feb 14, 2023	BUY	$5.26 - $12.19 $42,453 - $98,385	8,071 Added 78.25%	18,386 $112,000
Q3 2022 Nov 14, 2022	BUY	$9.86 - $15.76 $101,705 - $162,564	10,315 New	10,315 $123,000
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $121,456 - $187,558	-7,361 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $131,099 - $183,068	7,361 New	7,361 $169,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.